Inflammatory peroxidases promote breast cancer progression in mice via regulation of the tumour microenvironment

VASILIOS PANAGOPOULOS1, DAMIEN A. LEACH1, IRENE ZINONOS1, VLADIMIR PONOMAREV2, GIOVANNI LICARI1, VASILIOS LIAPIs1, WENDY V. INGMAN1, PETER ANDERSON3, MARK O. DeNICHILO1 and ANDREAS EVDOKIIOU1

1Discipline of Surgery, Breast Cancer Research Unit, Basil Hetzel Institute and Centre for Personalised Cancer Medicine, University of Adelaide, Adelaide, SA, Australia; 2Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 3Australian Craniofacial Unit, Women's and Children's Health Network, Adelaide, SA, Australia

Received October 18, 2016; Accepted November 28, 2016

DOI: 10.3892/ijo.2017.3883

Abstract. Myeloperoxidase (MPO) and eosinophil peroxidase (EPO) are heme-containing enzymes, well known for their antimicrobial activity, are released in high quantities by infiltrating immune cells in breast cancer. However, the functional importance of their presence within the tumour microenvironment is unclear. We have recently described a new role for peroxidases as key regulators of fibroblast and endothelial cell functionality. In the present study, we investigate for the first time, the ability of peroxidases to promote breast cancer development and progression. Using the 4T1 syngeneic murine orthotopic breast cancer model, we examined whether increased levels of peroxidases in developing mammary tumours influence primary tumour growth and metastasis. We showed that MPO and EPO stimulation increased mammary tumour growth and enhanced lung metastases, effects that were associated with reduced tumour necrosis, increased collagen deposition and neo-vascularisation within the primary tumour. In vitro, peroxidase treatment, robustly stimulated human mammary fibroblast migration and collagen type I and type VI secretion. Mechanistically, peroxidases induced the transcription of pro-tumorigenic and metastatic MMP1, MMP3 and COX-2 genes. Taken together, these findings identify peroxidases as key contributors to cancer progression by augmenting pro-tumorigenic collagen production and angiogenesis. Importantly, this identifies inflammatory peroxidases as therapeutic targets in breast cancer therapy.

Introduction

It is well-established that chronic inflammation is a critical component of tumour development and progression (1,2). However, many of the molecular and cellular factors involved remain obscure. Infiltrating neutrophils and eosinophils have been observed in most human cancers and are often associated with poor survival (3-5). Recently, neutrophils have gained considerable attention as important players in cancer progression because of their role in ECM remodeling, tumour angiogenesis and metastasis (6-8). Moreover, Chen et al (5) revealed that an elevated peripheral neutrophil/lymphocyte ratio was associated with poor survival in breast cancer.

Within the tumour microenvironment, the accumulation of neutrophils is reported within the invasive front of tumours (9,10), while eosinophils abundantly accumulate near blood vessels and infiltrate hypoxic regions (11,12), where they are activated to release an arsenal of factors from their cytoplasmic granules. A major component of these released factors are myeloperoxidase (MPO) and eosinophil peroxidase (EPO), which are released by infiltrating neutrophils and eosinophils, respectively. Importantly, these enzymes are abundantly deposited in breast cancer (4,13). However, to date, no distinct role has been attributed to their presence within the tumour microenvironment. We have recently reported a new biological role for peroxidase enzymes as key regulators of fibroblasts and endothelial cell functionality, driving migration, collagen biosynthesis and blood vessel development (14,15), processes which are major contributors of cancer development and metastasis (16).
In the present study, we investigated for the first time the pro-tumorigenic and pro-metastatic potential of MPO and EPO using the 4T1 syngeneic breast cancer mouse model and characterized the molecular mechanisms involved. In vitro, peroxidase treatment stimulated primary human mammary fibroblast migration, collagen type I and VI protein secretion, and modified ECM architecture. In vivo, peroxidases enhanced mammary tumour growth and progression. Taken together, our findings identify peroxidase enzymes as key mediators of tumour development and progression, and suggest that peroxidase inhibitors may have therapeutic potential for the treatment of breast cancer and metastasis.

Materials and methods

Reagents. Native human eosinophil peroxidase (EPO) was obtained from Cell Sciences (Canton, MA, USA) and GenWay Biotech Inc. (San Diego, CA, USA). Recombinant human myeloperoxidase (MPO) was purchased from R&D Systems (Minneapolis, MN, USA).

Animals. Five week-old female BALB/c mice (Institute of Medical and Veterinary Services Division, Gilles Plains, SA, Australia) were acclimatized to the animal housing facility for a minimum period of 1 week prior to the commencement of experimentation. All mice were housed under pathogen free conditions and all experimental procedures on animals were carried out with strict adherence to the rules and guidelines for the ethical use of animals in research and were approved by the Animal Ethics Committees of the University of Adelaide and the Institute of Medical and Veterinary Science, Adelaide, SA, Australia.

Mammary fat pad injection of breast cancer cells. 4T1 mouse breast cancer cells were cultured in RPMI-1640 media, supplemented with 2 mM glutamine, 100 IU/ml penicillin, 160 µg/ml gentamicin, HEPES (20 mM) and 10% fetal bovine serum (FBS; Biosciences, Sydney NSW, Australia) in a 5% CO2-containing humidified atmosphere, until they reached 70-80% confluent. Adherent cells were removed from flasks with 0.5% trypsin/EDTA and resuspended in phosphate-buffered saline (PBS) at 0.5x10⁵ cells/10 µl and kept on ice in an Eppendorf tube. An equal volume of Matrigel™-HC (BD Biosciences, Bedford, MA, USA) was added to the cells and resuspended. Seven-week old mice were divided into 3 groups (n=7) and anaesthetized by isoflurane (Faulding Pharmaceuticals). Mice were injected into the intraperitoneal (i.p.) space with 100 µl of the D-Luciferin solution at final dose of 3 mg/20 g mouse body weight (Xenogen Corp.) and then gas-anaesthetized with isoflurane (Faulding Pharmaceuticals). Images were acquired for 0.5-30 sec (representative images are shown at 1 sec) from the front angle and the photon emission transmitted from mice was captured and quantitated in photons/sec using Living Image software (version 4.2).

Histochemistry analysis. Standard hematoxylin and eosin (H&E) staining of paraffin embedded tissue was used for histological examination of primary tumours. Stained sections were examined and photographed on a Nikon Eclipse 90i microscope. Tumour necrosis was assayed on H&E whole tumour cross-section and quantified by ImageJ software (NIH, Bethesda, MD, USA) as previously described (17). Briefly, H&E histological slides of whole tumour cross-sections were digitized, where areas of tumour borders and necrosis were assessed and highlighted as a separate pixelated area. The area of tumour necrosis was then quantified as a percentage of total tumour area. For immunohistochemistry, sections (6 µm thick) of 4T1 tumours were probed with primary antibodies; rabbit anti-human collagen type I polyclonal; rabbit anti-human collagen type VI polyclonal (Rockland Immunochemicals, Inc., Pottstown, PA, USA), mouse anti-human α-SMA (Sigma-Aldrich, St. Louis, MO, USA), rabbit anti-human CD31 (Abcam, Cambridge, UK) as previously described (14). Quantitative analysis of the degree of positive staining was performed by digitized image analysis with ImageJ software as previously described (18). Briefly, the image of the tissue area was converted to grey scale and the threshold level of staining was set for each image and measured and expressed as a percentage of the total tissue surface.

Transwell migration assay. Mammary fibroblast cell migration was determined using the 24-well Transwell plate (BD Falcon FluoroBlok™) system with 8.0 µm pore PET membranes. Fibroblasts were starved in serum-free Dulbecco's modified Eagle's medium (DMEM) overnight, then seeded (1x10⁵ cells) in 100 µl of serum-free DMEM into the upper wells and incubated at 37°C in 5% CO₂ for 30 min to allow cell adhesion. Lower chambers were then filled with 700 µl of serum-free DMEM with no further supplementation as the negative control, or supplementation with TGF-β (10 ng/ml) serving as the positive control, or with the various peroxidase proteins. Cells were allowed to migrate for 18 h. Migrated cells were fixed in 6:1 ethanol/acetic acid for 10 min, stained with DAPI (1 µg/ml), and then photographed and quantified on a fluorescent inverted microscope (Axio Observer Z1; Carl Zeiss AG, Oberkochen, Germany).

Collagen enzyme-linked immunosorbent assay (ELISA). To evaluate the effect of MPO and EPO on collagen production, human mammary fibroblasts were seeded into 96-well plates (Nunc, Roskilde, Denmark) at a density of 1.2x10⁵ cells/well and cultured for 5 days in DMEM/10% FBS until reaching confluence. Cells were starved overnight in serum-free DMEM and then stimulated for an additional 72 h in serum-free DMEM containing either ascorbic acid 2-phosphate at 10 µmol/l (Wako Chemical Industries, Ltd., Osaka, Japan) as a positive control,
or with the peroxidase proteins in the absence of ascobic acid supplementation. At the end of the 72-h treatment period, fibroblast-conditioned media were collected for measurement of secreted soluble type I and VI collagen by ELISA. Cell viability/growth was then assessed using the AlamarBlue® fluorescent dye assay (Invitrogen Life Technologies, Melbourne, Australia) as per manufacturer’s instructions. The amount of soluble type I and VI collagen in cell-conditioned medium was measured by a direct coat ELISA method using standard curves constructed from purified type I and VI human placental collagen (BD Biosciences) as previously described (14).

**3D matrix production.** To assess the effect of MPO and EPO on 3D collagen formation, 3D collagen matrices were generated by stimulated human mammary fibroblasts as previously described (19). Briefly, 24-well plates were treated with 0.2% gelatin in PBS overnight at 4°C, then cross-linked with paraformaldehyde and washed multiple times with PBS. Human mammary fibroblasts were seeded onto plates and grown to confluency. When cells reached 100% confluency, platting mammary fibroblasts were seeded into plates and grown to form 3D collagen matrices. Matrices were created in the upper chamber of a 24-well Transwell plate (BD Falcon FluoroBlok™) system with 8.0 µm pore PET membranes. 4T1 cells were then seeded (1x10⁵) in 100 µl of serum-free RPMI into the upper wells and incubated at 37°C in 5% CO₂ for 30 min to allow cell adhesion. Lower chambers were filled with 700 µl of reduced serum (2% FBS) RPMI as a chemo-attractant stimulus for 24 h. Migrated cells were then removed using cell lysis buffer, and the remaining ECM was washed multiple times with PBS prior to use in adhesion, invasion and immunofluorescence assays.

**Immunofluorescence assays.** Human mammary fibroblasts were seeded onto circular glass coverslips where 3D collagen matrices were generated. Matrices were blocked with goat serum in PBS Triton-X, before washing and immune-labeled overnight with antibodies against collagen type I (Rocklands Immunocchemicals). Labeled proteins were detected using Alexa Fluor® 488 goat anti-mouse IgG (Molecular Probes/Thermo Fisher Scientific Australia Pty Ltd., Scoresby VIC, Australia). Fluorescence was captured using a laser confocal microscope (Zeiss LSM 700; Carl Zeiss AG).

**4T1 mammary carcinoma adhesion assay.** Using 3D-ECM matrices created from fibroblasts, adherence of 4T1 cancer cells was assessed via adhesion assays previously described (20). Briefly, 2x10⁴ cells were applied to 3D-ECMs in 24-well plates and were allowed to adhere for 4 h. Cells were then gently washed with PBS before the cell measurement via AlamarBlue® assay as per manufacturer's instructions.

**4T1 mammary carcinoma invasion assay.** Three-dimensional (3D) ECM invasion assays were adapted from a previously described study (21). Mammary fibroblast derived 3D-ECM matrices were created in the upper chamber of a 24-well Transwell plate (BD Falcon FluoroBlok™) system with 8.0 µm pore PET membranes. 4T1 cells were then seeded (1x10⁵) in 100 µl of serum-free RPMI into the upper wells and incubated at 37°C in 5% CO₂ for 30 min to allow cell adhesion. Lower chambers were filled with 700 µl of reduced serum (2% FBS) RPMI as a chemo-attractant stimulus for 24 h. Migrated cells on the opposite side of the Transwell membrane were fixed in 6:1 ethanol/acetic acid for 10 min, stained with DAPI (1 µg/ml), and then photographed and quantified on a fluorescence inverted microscope (Axio Observer Z1; Carl Zeiss AG).

**4T1 mammary carcinoma proliferation assay.** Proliferation of sub-confluent 4T1 cultures was assessed by alamarBlue, as previously described (22). Briefly, 4T1 (1x10⁵) cells were cultured in 96-well plates in 100 µl in 2% FBS RPMI media. Cells were treated with 100 µl of increasing concentrations of MPO and EPO (0.31-5 µg/ml) at the time of cell plating and cultured for 48 h. FBS RPMI growth media (10%) served as the positive control. The fluorescence was measured and quantified at wavelengths of 530 nm excitation and 595 nm emission using FLUOStar Optima microplate reader (BMG Labtech, Ortenberg, Germany).

**RNA isolation and quantitative real-time PCR.** To evaluate the effect on human mammary fibroblast and 4T1 mammary carcinoma gene regulation by MPO and EPO (2 µg/ml), RT-PCR was performed. RNA isolation and cDNA synthesis was performed as previously described (14). Messenger RNA expression of specific genes was identified using real-time RT-PCR using SYBR-Green Fluor qPCR Mastermix (Qiagen) in a CFX96 real-time system (Bio-Rad Laboratories) as previously described (23). The primer combinations used are as follows: cyclooxygenase-2 (COX-2): forward, 5'-CCTGTG CCTGTGATTTGC-3' and reverse, 5'-CTGATGCTGGAAATG TGGCTG-3'; matrix metalloproteinase 1 (MMP1): forward, 5'-GACGTCCCCAAAATC-3' and reverse, 5'-GCTAGAAG GGATTG-3'; matrix metalloproteinase 3 (MMP3): forward, 5'-AGAGGACATCACACC-3' and reverse, 5'-CTGGCCTCA TGGAATTCTCTTC-3'; Expression values were normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH): forward, 5'-ACCCAGAAGACTCTGTG CCTGTGATTTGC-3' and reverse, 5'-AGAGGACATCACACC-3'.

**Data analysis and statistical analysis.** Data points derived from experiments are reported as the mean ± standard error of the mean (SEM). Analysis of variance to determine significant difference between samples was performed using the paired Student’s t-test, and one way ANOVA followed by multiple comparison test (Dunnett's Method) where indicated, using SigmaPlot 2011 (version 12.0, Systat Software, Inc., San Jose, CA, USA).

**Results**

**Peroxidases enhance primary tumour growth in vivo.** To evaluate the role of MPO and EPO in mammary tumour growth and metastasis, we used a bioluminescent, luciferase labeled 4T1 mouse mammary carcinoma cell line, and the subsequent orthotopic 4T1 tumour metastasis model in BALB/c mice. 4T1 cells were inoculated into the 4th mammary fat pad of BALB/c mice and allowed one week for tumour establishment before once weekly intratumoral injections of 5-µg doses of MPO or EPO, with PBS serving as the vehicle control. Tumour growth was monitored weekly with non-invasive bioluminescence imaging (BLI) (Fig. 1A), and quantified via luciferase intensity (photons/sec) (Fig. 1B), which showed that both MPO and EPO treatment increased primary tumour growth (MPO, P=0.05), over 23 days, as compared to the vehicle control.
Tumour burden measured also by calipers and expressed as a function of volume in mm$^3$ confirmed the BLI ($P<0.05$; Fig. 1C and D).

Histological examinations of the 4T1 tumours after 23 days (Fig. 2A) showed that tumour necrosis was significantly decreased by MPO and EPO treatment. Representative images of H&E staining clearly show the inherent necrotic and avascular regions within the PBS treated 4T1 primary tumour in the control mice. In contrast, treatment with either peroxidase, show diminished regions of necrotic areas that were associated with the presence of viable tumour cells. Histological staining and subsequent quantitative image analysis of tumour sections with antibodies to CD31, α-SMA and collagen types I and VI, identified and increase in vascularization, myofibroblasts and ECM deposition, respectively (Fig. 2B).

**Peroxidases enhance lung metastasis.** Mammary carcinoma 4T1 cells spontaneously metastasize to the lungs from the mammary fat pad (24). Histological assessment of excised lungs stained with H&E confirmed the presence of lung metastasis indicating an increase in macrometastases in the lungs of animals treated with peroxidases (Fig. 3A). *Ex vivo* BLI quantification of excised lungs from animals in each group confirmed these findings as a function of photon counts per sec. Both MPO and EPO treatment groups revealed an increase in the intensity (photons/sec) representative of increased spontaneous lung metastasis (MPO, $P<0.05$; EPO, $P=0.12$) after 23 days relative to vehicle control (Fig. 3B). Thus, our data indicate that an increase in peroxidase levels within the primary tumour has the potential to promote metastatic spread to the lungs in vivo.

**Peroxidases promote pro-fibrotic effects in primary human mammary fibroblasts in vitro.** The migratory ability of fibroblasts within the tumour microenvironment plays a central role in tumour growth and is causatively associated with increased metastatic behaviour of cancer cells (25). To determine the effect of peroxidases on primary human mammary fibroblasts, we measured cellular movement toward MPO and EPO using a Transwell migration assay. After 24 h in serum-free conditions, MPO and EPO (5 µg/ml) significantly increased mammary fibroblast migration by 2- and 4-fold, respectively,
when compared to vehicle control (P<0.05; Fig. 4A). The stimulation of primary human mammary fibroblasts with increasing concentrations of MPO and EPO in the absence of ascorbic acid (AA) demonstrated a dose-dependent increase in collagen type I (Fig. 4B) and type VI (Fig. 4C) up to 2- and 1.6-fold, respectively (P<0.0001, P<0.001 and P<0.05).

At these peroxidase concentrations, there was no impact on the proliferation and/or viability of the confluent mammary fibroblasts. To determine the potential for other mechanisms by which peroxidases activate fibroblasts, we next investigated the transcriptional regulation of the key genes implicated in promoting a motile phenotype (Fig. 4D) including COX-2 and the matrix modifying genes MMP1 and MMP3 via RT-PCR (26). Analysis of mRNA expression showed that MPO and EPO increased COX-2 expression 2.5- and 3.7-fold, MMP1 expression 2- and 2.9-fold, and MMP3 expression 1.8- and 4.2-fold, respectively, when compared to vehicle control (P<0.0001, P<0.001 and P<0.05).

Peroxidases promote a functional pro-tumorigenic ECM in vitro. Collagen fiber alignment plays a critical role in tumour progression (27). Immunofluorescent detection of collagen type I orientation within cell derived 3D collagen matrices (Fig. 5A) showed that MPO (MPO-ECM) and EPO...
Figure 3. Effects of peroxidases on pulmonary metastasis. (A) Representative histological sections of lungs from each group stained with H&E, arrows indicate the presence of macrometastasis, with showing an increase of tumour burden within the lungs of peroxidase treated mice. (B) Quantification of bioluminescent tumour signal in the lungs measured as average photon counts per second, with representative BLI images from each treatment group inoculated with 4T1 cells after 23 days. Results are shown as the mean ± SEM. Statistical significance was calculated by ANOVA (*P<0.05). Scale bar, 500 µm.

Figure 4. Peroxidases promote profibrotic effects in human mammary fibroblasts in vitro. (A) Transwell migration assay. Human mammary fibroblasts (5x10^4) were placed onto the membrane well of a Transwell insert in the presence of treatment medium in the lower chamber. Cells treated with serum-free culture media served as the vehicle control, TGF-β (10 ng/ml) served as the positive control, while MPO and EPO (5 µg/ml) were used as test. Migrated cells were stained with DAPI after 24 h and were counted from five fields of view in triplicate wells. Enzyme-linked immunosorbant assay detection of soluble collagen type I (B), and type VI (C) in primary human mammary fibroblasts conditioned media after 72 h of stimulation with MPO and EPO at the doses indicated. Ascorbic acid 2-phosphate (AA) at 10 µM served as the positive control, whereas cells treated with serum-free culture media (DMEM) alone served as the vehicle control. The levels of collagen are expressed as fold change compared to vehicle control. (D) RT-qPCR analysis of mRNA from an independent set of triplicate human mammary fibroblast samples, stimulated with MPO or EPO (0.5 µg/ml) after 48 h for gene expression of (a) COX-2, (b) MMP1 and (c) MMP3. Data were normalized to the housekeeping gene GAPDH and expressed as fold change compared to vehicle control. Representative data are shown as the mean ± SEM performed in quadruplicate of two independent experiments. Statistical significance was calculated by the Student's t-test (‡P<0.0001, †P<0.001, *P<0.05).
(EPO-ECM) stimulation produced a matrix of parallel and/or linearized collagen fibers comparable to the AA (AA-ECM) positive control. In contrast, the unstimulated vehicle control matrices (VC-ECM) display a mesh-like and disorganized organization of random collagen fibers.

To determine whether this increase in the alignment of collagenous matrix affects tumour cell behaviour, we next tested the adherent properties of the different ECM by measuring 4T1 tumour cell adhesion to the matrices produced under different conditions. After 4 h of co-incubation, MPO-ECM and EPO-ECM significantly increased 4T1 adhesion up to 15% (P<0.01) and 25% (P<0.001), respectively, when compared to VC-ECM. The response was similar to
that achieved by the AA-ECM (Fig. 5B). Collagen alignment facilitates invasion, thus, to further understand how the reorganization of aligned collagen fibers interacts with tumour cells, we tested the effects of the peroxidase-modified matrices on the 4T1 cells in a Transwell system designed to monitor cell movement through fibroblast generated ECM. After a 24-h period in reduced serum conditions, cell counts showed that the peroxidase induced 3D matrices of MPO and EPO significantly increased 4T1 invasion ~1.5-fold (P<0.001) compared to vehicle control, a response similar to that seen by the positive control, AA (Fig. 5C).

**Peroxidases exhibit direct effects on 4T1 tumour cells.** To explore further the role of increased peroxidase presence within the tumour microenvironment, we investigated the proliferation, migration/invasion, and mechanistic aspects of 4T1 tumour cells stimulated with either MPO or EPO. Treatment of 4T1 cells with various concentrations of peroxidases had no effect on proliferation after 48 h when compared to vehicle control (Fig. 6A), while 10% FBS containing media served as the positive control. However, using the Transwell migration system, the chemo-attractant ability of MPO and EPO significantly increased migration almost 2-fold (P<0.0001) and 4-fold (P<0.0001) respectively when compared to vehicle control (Fig. 6B). MMP1 gene expression belongs to a subset of genes that are associated with organ specific metastasis to the lungs (28). To investigate the transcription regulation of MMP1, we analyzed peroxidase treated 4T1 tumour cells via RT-PCR. Analysis of mRNA expression showed that MPO and EPO increased MMP1 expression 3- and 2-fold, respectively when compared to vehicle control (P<0.05).

**Discussion**

It is well established that inflammatory cells have commanding effects on tumour development and that both MPO and EPO are found at high levels within the stroma of human breast cancers and breast tumours in mouse models (4,29). The present study is the first to uncover a mechanism linking peroxidases with facilitating tumour growth and metastasis via the regulation of ECM components and angiogenesis. Studies have shown that the depletion of neutrophils can significantly reduce collagen-dense mammary tumour progression (6) and angiogenesis (30), suggesting that these immune cells and their constituents are key players in tumour formation and metastasis.

Using the murine 4T1 breast cancer model we showed that when injected into the tumour microenvironment, MPO and EPO significantly increased tumour growth and evidence of enhanced metastasis to the lungs. Our unique findings are supported by a recent study showing that specific inhibition of MPO catalytic activity during the early stages of tumour development reduced tumour burden by 50% in a model of lung carcinogenesis (31). This finding suggests a causative role for MPO during tumorigenesis, and identifies MPO inhibitors as novel therapeutic agents. Furthermore, earlier studies have identified that women with a genetic polymorphism responsible with reduced MPO expression is associated with reduced breast cancer risk (32,33). Taken together, these studies suggest a more sinister role for these inflammatory enzymes. Our histological analysis of the peroxidase-treated tumours, showed a reduction of necrosis within the necrotic cores inherent of the 4T1 tumours (34). This suggests that MPO and EPO may promote the survival of cancer cells likely via the activation of the stroma compartment since peroxidases had no direct effects on tumour cells themselves.

Peroxidases induced an increase in stromal fibroblasts within the primary tumour and collagen I and VI deposition. Enhanced deposition of collagens and the aberrant changes through the remodeling of ECM composition and function within the tumour microenvironment are crucial for facilitating primary tumour growth and escape (35). Specifically, increased collagen type I is a prognostic factor and is associated with breast cancer recurrence in human breast cancer patients (36), while collagen type VI knockout mice were shown to have reduced primary tumour formation and growth (37). Importantly, the peroxidase effects on primary human mammary fibroblasts in vitro appear to correlate with our histological observations in vivo, as we find that both MPO and EPO regulate fibroblast migration and/or recruitment shown by an increase in α-SMA staining within the primary tumours, as well as increased collagen type I and VI deposition.

Studies have shown that ECM configuration in particular, collagen fiber alignment (27) and tissue stiffness (38) are functionally associated with tumour invasion. In this study, we find that both MPO and EPO, in addition to increasing collagen biosynthesis, alter collagen alignment in a 3D matrix. Our results further show, that the combination of increased collagen biosynthesis with the structural shift in the alignment of collagen fibers in the absence of AA, significantly increased tumour cell adhesion and invasion, however, due to the dramatic ability of peroxidases to stimulate collagen, it may be conceivable that more collagen is sufficient to exert these effects. To accurately recapitulate these effects in vivo, further studies are needed to confirm whether the peroxidase-induced alignment observed in the present study affects overall tumour stiffness as reported by Acerbi and colleagues (39). Intriguingly, the authors of this study revealed that a correlation between the invasive regions of aggressive human breast cancer and ECM remodeling and stiffening was linked to an increase in innate immune infiltrate. Although, it is widely accepted that elevated collagen deposition coupled with the alteration of linear collagen fibers lead to an increase in ECM stiffness (40,41), further exploration is needed to determine the stromal features that contribute to tumour stiffness.

Aberrant MMP activities within the stromal compartment have a causative role in tumour incidence by affecting tumour cell motility and invasiveness. In the present study, we showed that both MPO and EPO modulate MMP1 and MMP3 gene expression in primary human mammary fibroblasts, while increasing the transcription of MMP1 in 4T1 mammary carcinoma epithelial cells. Elevated MMP1 expression in CAFs has been linked to vital metastatic processes that facilitate angiogenesis, matrix degradation and the conversion of normal resident fibroblasts to activated CAFs (42). In addition, several independent studies reported that the overexpression of MMP3 within the mammary stroma, increases mammary tumour incidence and invasion (43-45), while the overexpression of MMP1 in mammary epithelial cells is associated with
increased invasion, and metastasis to the lungs, brain and the bone (28,46-48). We have recently shown that MPO and EPO modulate the transcriptional regulation of COX-2 in primary human endothelial cells (15). Here, we show that peroxidases also regulated COX-2 gene expression in primary human fibroblasts. However, no significant effect was found in murine 4T1 carcinoma cells (data not shown). Based on the increased expression in a large portion of breast carcinomas, the activation of COX-2 and MMPs have been implicated to have a significant role in accelerating breast tumorigenesis and necessary for the initiation of metastasis, particularly to the lungs (49). Emerging evidence reveals that stromal COX-2 expression can also function as a mediator of tumour progression (50,51).

In summary, our findings demonstrate for the first time that the peroxidase enzymes MPO and EPO confer a broader range of action than previously thought and exhibit potent pro-tumorigenic effects in the tumour milieu altering matrix composition and function, angiogenesis and invasion. Taken together with our previous reported observations, we propose that both MPO and EPO are causatively involved in breast cancer progression and identify them as potential therapeutic targets whereby specific novel inhibitors may reduce tumour growth and limit the occurrence of metastasis.

Acknowledgements

We thank Matthew Iasiello for his excellent technical assistance. The present study was supported in part by The Hospital Research Foundation and the National Health and Medical Research Council (Career Development Fellowship/627015; Project Grant/1050694).

References